The field of Biotechnology started emerging during the period of Rajiv Gandhi in 1968. Back then, Biotechnology evolved and was placed for support by the gorvenment to encourage. After this revolutionary forward, India turns out as the pharma hub for world, it becomes the key player in generic medicine supply amid the rest of the world, it also supplies about 20% of the generic drugs per annum globally. With motivational support from governmental funding agents like BIRAC- DBT owned, latest technologies in medicine have been rendered to commercialization. It is important for India to elevate its research and laboratory, making up a growing economy, in mankind’s benefit. There are lots of upcoming technologies from diverse subject areas to require extensive trials and differential integration for product/service conversion.
Biotechnology is one such focused area in interest with diverse streamlined subjects, that realizes into unique technology, one a day, from globally pooled contribution. India is considered to be in the top twelve destinations of the emerging industry with a 3% global share. Past the end of Human Genome Project (HGP), Indian entrepreneurs fragmented the sector into five focus fields: Bioinformatics, Bio-Agri, Bio-pharma, Bio-services and Bio-industrial. Further then, some recently developing commercial technologies are Monoclonal Antibodies, Wide Genome Analysis and personalized medicine. These technologies contribute extensively in different forms for drug and vaccine production to specifically target diseases in prevention of cross reactivity. Monoclonal Antibody production technology has simplified the chemical R&D for synthesizing new compounds against any disease. Similarly, Wide Genome Analysis represents, each individual’s genes inherited from parents well as by mutations occurred in lifestyle make the genome individually differentiable. Hence the complex analysis of each genome particularly is helpful in diagnosis besides prognosis of a person. One such revolutionary technology in recent times is the development of personalized medicine. The technology is all about reading an entire genome in minimal hours to be stored on a chip. With an advancement in whole-genome sequencing, time-consuming Sanger di deoxy technique precedes the next-gen sequencing method by Illumina, providing many opportune tech-revolve spaces.
Under the notion- each of us being unique, follows a subsidiary that a drug efficient to one might not necessarily be so to another; and here shoots up, the market, for a medical personalization. Healthcare carries within, variegated themes. Such relevant technologies’ potentials add up to cause a synergistic effect hence companies from different industries are trailblazing to interlink these technologies beneath a single roof. The integrating technologies do not limit to Biotechnology only, rather extends upto interdisciplinaries: Artificial Intelligence, Machine Learning technology, Smart Grid sensors with 5G Communication-enabled systems etc.,
The personalised medicine uses the advent of quicker sequencing by Illumina methodology in reading human genome. This technique not just bests personalised drug design, reduces also side effects whilst helping in risk assessments. This approach works well on Cancer, Cardio Vascular diseases, Auto-immune disorders analyzing Graft vs Host rejection, etc. Several start-ups emerge holding up this technology. GANIT, Medicity, Xcode Lifesciences, Global Gene Corp, MedGenom .are firms basing this technology; in 2017 MedGenome secured a Rs.192 crore sum in funding, later they won MedTech Breakthrough award. Some developing startups in India are working on establishing roots of these technologies, namely, Live Health, Niramai, Practo, Mitra Biotech. These companies have contributed to Indian economy by 7% and together make up for 1.2% of the total GDP. These startups also raise demand for accuracy, efficiency and transparency in healthcare sector.
Thus provides one best platform for Indian start-ups to explore and create significance towards fine future, Personalized Medicine.
Comments